Diabetes medications and body weight

被引:99
作者
Mitri, Joanna [2 ]
Hamdy, Osama [1 ]
机构
[1] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02481 USA
[2] Boston Univ, Sch Med, Roger Williams Hosp, Providence, RI USA
关键词
diabetes; diabetes medications; insulin; oral antidiabetic medications; weight gain; weight loss; weight management; Why WAIT program; DRUG-NAIVE PATIENTS; BEDTIME NPH INSULIN; IMPROVES GLYCEMIC CONTROL; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; NEUTRAL PROTAMINE HAGEDORN; LIFE-STYLE MODIFICATION; DOUBLE-BLIND; COMBINATION THERAPY; PIOGLITAZONE HYDROCHLORIDE; EXENATIDE EXENDIN-4;
D O I
10.1517/14740330903081725
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Tight diabetes control sometimes comes with a price: weight gain and hypoglycemia. Two of the three major recent trials that looked at the relationship between intensive diabetes control and cardiovascular events reported significant weight gain among the intensively treated groups. There is a growing concern that the weight gain induced by most diabetes medications diminishes their clinical benefits. On the other hand, there is a claim that treating diabetes with medications that are weight neutral or induces weight loss or less weight gain while minimizing those that increase body weight may emerge as the future direction for treating overweight and obese patients with diabetes. This review clarifies the weight effect of each of the currently available diabetes medications, and explains the mechanism of action behind this effect. Despite the great variability among reviewed clinical trials, the currently available evidence is quite sufficient to demonstrate the change in body weight in association with most of the currently available medications. This review also provides some guidelines on using diabetes medications during weight management programs.
引用
收藏
页码:573 / 584
页数:12
相关论文
共 126 条
[1]   Standards of Medical Care in Diabetes-2009 [J].
不详 .
DIABETES CARE, 2009, 32 :S13-S61
[2]  
[Anonymous], 1995, BMJ, V310, P83, DOI DOI 10.1136/BMJ.310.6972.83
[3]   Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes - A 6-month randomized placebo-controlled dose-response study [J].
Aronoff, S ;
Rosenblatt, S ;
Braithwaite, S ;
Egan, JW ;
Mathisen, AL ;
Schneider, RL .
DIABETES CARE, 2000, 23 (11) :1605-1611
[4]   Increased protein synthesis after acute IGF-I or insulin infusion is localized to muscle in mice [J].
Bark, TH ;
McNurlan, MA ;
Lang, CH ;
Garlick, PJ .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1998, 275 (01) :E118-E123
[5]   Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial [J].
Barnett, Anthony H. ;
Burger, Jude ;
Johns, Don ;
Brodows, Robert ;
Kendall, David M. ;
Roberts, Anthony ;
Trautmann, Michael E. .
CLINICAL THERAPEUTICS, 2007, 29 (11) :2333-2348
[6]   DISTURBANCE OF INTESTINAL ABSORPTION FOLLOWING METFORMIN THERAPY (OBSERVATIONS ON MODE OF ACTION OF BIGUANIDES) [J].
BERCHTOL.P ;
BOLLI, P ;
ARBENZ, U ;
KEISER, G .
DIABETOLOGIA, 1969, 5 (06) :405-&
[7]   PHYSIOLOGICAL HYPERINSULINEMIA STIMULATES PROTEIN-SYNTHESIS AND ENHANCES TRANSPORT OF SELECTED AMINO-ACIDS IN HUMAN SKELETAL-MUSCLE [J].
BIOLO, G ;
FLEMING, RYD ;
WOLFE, RR .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (02) :811-819
[8]   Meglitinide analogues for type 2 diabetes mellitus (Review) [J].
Black, C. ;
Donnelly, P. ;
McIntyre, L. ;
Royle, P. L. ;
Shepard, J. P. ;
Thomas, S. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (02)
[9]  
Boehm Bernhard O, 2004, Eur J Intern Med, V15, P496, DOI 10.1016/j.ejim.2004.10.001
[10]   Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat [J].
Braissant, O ;
Foufelle, F ;
Scotto, C ;
Dauca, M ;
Wahli, W .
ENDOCRINOLOGY, 1996, 137 (01) :354-366